Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

Despite sound science, many recent drug launches are failing. The root cause is not the data but an underinvestment in market conditioning. Cautious investors and tighter budgets mean companies are starting their educational and scientific storytelling efforts too late, failing to prepare the market adequately.

The standard patent system, which rewards innovation through high prices, is inefficient for creating products for the poor like vaccines. Advanced Market Commitments (AMCs) solve this by creating a pull mechanism: a legally binding promise to buy a large quantity at a set price, guaranteeing a market and aligning incentives for innovation.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

Developing an antibiotic is costly, but its use is short-term and new drugs are held in reserve, making them unprofitable. This market failure, not a lack of scientific capability, has caused pharmaceutical companies to exit the space, creating a worsening global health crisis.

To fix market failures in drug development, sophisticated economic tools are used. Priority Vouchers let a firm fast-track an unrelated profitable drug, while Advanced Market Commitments (AMCs) are binding government promises to buy a future vaccine, guaranteeing a market where none exists.

Selling low-cost vaccines to organizations like Gavi isn't just charity for pharmaceutical companies. It creates massive economies of scale, lowering the cost of goods for their high-margin primary markets and increasing overall net profit, creating a powerful win-win incentive structure.

Diseases like Ebola and malaria, which primarily affect poor countries, lack market incentives for vaccine R&D. The Ebola vaccine only progressed because it was briefly on a U.S. bioterrorism list created after 9/11, highlighting how market failures require creative, sometimes accidental, incentives to overcome.

For diseases affecting only the poorest populations, scientific success isn't enough. The key financial instrument is an "advanced purchase" guarantee from a government or large organization. This de-risks production for manufacturers, providing a viable business model where traditional profit motives fail.